ATE482210T1 - Oxadiazolderivate als s1p1-rezeptor-agonisten - Google Patents

Oxadiazolderivate als s1p1-rezeptor-agonisten

Info

Publication number
ATE482210T1
ATE482210T1 AT07857804T AT07857804T ATE482210T1 AT E482210 T1 ATE482210 T1 AT E482210T1 AT 07857804 T AT07857804 T AT 07857804T AT 07857804 T AT07857804 T AT 07857804T AT E482210 T1 ATE482210 T1 AT E482210T1
Authority
AT
Austria
Prior art keywords
receptor agonists
oxadiazole derivatives
formula
treatment
pharmaceutical compositions
Prior art date
Application number
AT07857804T
Other languages
English (en)
Inventor
Mahmood Ahmed
James Myatt
David Norton
Dean Andrew Rivers
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ATE482210T1 publication Critical patent/ATE482210T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AT07857804T 2006-12-21 2007-12-19 Oxadiazolderivate als s1p1-rezeptor-agonisten ATE482210T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0625648.1A GB0625648D0 (en) 2006-12-21 2006-12-21 Compounds
PCT/EP2007/064181 WO2008074820A1 (en) 2006-12-21 2007-12-19 Oxadiazole derivatives as s1p1 receptor agonists

Publications (1)

Publication Number Publication Date
ATE482210T1 true ATE482210T1 (de) 2010-10-15

Family

ID=37734705

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07857804T ATE482210T1 (de) 2006-12-21 2007-12-19 Oxadiazolderivate als s1p1-rezeptor-agonisten

Country Status (7)

Country Link
US (1) US20100048639A1 (de)
EP (1) EP2091950B1 (de)
AT (1) ATE482210T1 (de)
DE (1) DE602007009420D1 (de)
ES (1) ES2352859T3 (de)
GB (1) GB0625648D0 (de)
WO (1) WO2008074820A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190004843A (ko) 2008-07-23 2019-01-14 아레나 파마슈티칼스, 인크. 자가면역성 및 염증성의 장애의 치료에 유용한 치환된 1,2,3,4-테트라히드로시클로펜타[ｂ]인돌-3-일)아세트산 유도체
JP5726737B2 (ja) 2008-08-27 2015-06-03 アリーナ ファーマシューティカルズ， インコーポレイテッド 自己免疫障害および免疫性障害の治療において有用なｓ１ｐ１受容体のアゴニストとしての置換三環式酸誘導体
JP2012515787A (ja) 2009-01-23 2012-07-12 ブリストル−マイヤーズ スクイブ カンパニー 自己免疫疾患および炎症性疾患の処置におけるｓ１ｐアゴニストとしての置換オキサジアゾール誘導体
WO2010085584A1 (en) 2009-01-23 2010-07-29 Bristol-Myers Squibb Company Pyrazole-i, 2, 4 -oxad iazole derivatives as s.phing0sine-1-ph0sphate agonists
WO2010085582A1 (en) 2009-01-23 2010-07-29 Bristol-Myers Squibb Company Substituted oxadiazole derivatives as s1p agonists in the treatment of autoimmune and inflammatory diseases
DE102009008256A1 (de) * 2009-02-10 2010-08-12 Lts Lohmann Therapie-Systeme Ag Prodrugs vom Typ N-hydroxylierter Amidine, Guanidine und/oder Aminohydrazone zur Applikation über die Haut
EP2241558A1 (de) * 2009-04-03 2010-10-20 Merck Serono SA Oxadiazolderivate
AR076984A1 (es) 2009-06-08 2011-07-20 Merck Serono Sa Derivados de pirazol oxadiazol
US20110034469A1 (en) 2009-08-04 2011-02-10 Takeda Pharmaceutical Company Limited Heterocyclic Compound
US8399451B2 (en) 2009-08-07 2013-03-19 Bristol-Myers Squibb Company Heterocyclic compounds
WO2011059784A1 (en) 2009-10-29 2011-05-19 Bristol-Myers Squibb Company Tricyclic heterocyclic compounds
CN108558740B (zh) 2010-01-27 2021-10-19 艾尼纳制药公司 S1p1受体调节剂及其盐的制备方法
CA2789480A1 (en) 2010-03-03 2011-09-09 Arena Pharmaceuticals, Inc. Processes for the preparation of s1p1 receptor modulators and crystalline forms thereof
EP2560969B1 (de) 2010-04-23 2015-08-12 Bristol-Myers Squibb Company 4-(5-isoxazolyl und 5-pyrrazolyl-1,2,4-oxadiazol-3-yl)-mandelsäureamide als sphingosin-1-phosphate 1 rezeptor agonisten
EP2595969B1 (de) 2010-07-20 2015-04-22 Bristol-Myers Squibb Company Substituierte 3-Phenyl-1,2,4-Oxadiazolverbindungen
WO2012040532A1 (en) 2010-09-24 2012-03-29 Bristol-Myers Squibb Company Substituted oxadiazole compounds and their use as s1p1 agonists
WO2012061459A1 (en) 2010-11-03 2012-05-10 Bristol-Myers Squibb Company Heterocyclic compounds as s1p1 agonists for the treatment of autoimmune and vascular diseases
EP2567959B1 (de) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridin-4-carbonsäureamid-derivate als kinaseinhibitoren
RU2014135795A (ru) 2012-02-03 2016-03-27 Новартис Аг Способ получения этилового эфира n-(4-циклогексил-3-трифторметилбензилокси)ацетимидовой кислоты
UY35338A (es) 2013-02-21 2014-08-29 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Compuestos bicíclicos moduladores de la actividad de s1p1 y composiciones farmacéuticas que los contienen
TWI689487B (zh) 2014-08-20 2020-04-01 美商必治妥美雅史谷比公司 經取代雙環化合物
PL3242666T3 (pl) 2015-01-06 2025-02-17 Arena Pharmaceuticals, Inc. Związek do zastosowania w leczeniu dolegliwości związanych z receptorem s1p1
HUE060476T2 (hu) 2015-06-22 2023-03-28 Arena Pharm Inc (R)-2-(7-(4-ciklopentil-3-(trifluormetil)benziloxi)-1,2,3,4- tetrahidrociklopenta[B]indol-3-il)ecetsav kristályos L-arginin-sója S1P1 receptorral kapcsolatos rendellenességek esetén való alkalmazásra
WO2018045149A1 (en) 2016-09-02 2018-03-08 Bristol-Myers Squibb Company Substituted tricyclic heterocyclic compounds
CN110545848A (zh) 2017-02-16 2019-12-06 艾尼纳制药公司 用于治疗具有肠外表现的炎症性肠病的化合物和方法
WO2018151873A1 (en) 2017-02-16 2018-08-23 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis
TWI886480B (zh) * 2017-04-06 2025-06-11 美商富曼西公司 殺真菌之噁二唑
WO2019032632A1 (en) 2017-08-09 2019-02-14 Bristol-Myers Squibb Company ALKYLPHENYL COMPOUNDS
WO2019032631A1 (en) 2017-08-09 2019-02-14 Bristol-Myers Squibb Company Oxime ether compounds
US12156866B2 (en) 2018-06-06 2024-12-03 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
EP3847158A1 (de) 2018-09-06 2021-07-14 Arena Pharmaceuticals, Inc. Verbindungen zur verwendung bei der behandlung von autoimmun- und entzündlichen erkrankungen
KR102215526B1 (ko) 2020-05-19 2021-02-15 브릿지테크놀러지(주) 세그먼트 연결장치를 이용한 프리캐스트 수직구 및 그 시공방법
CN116836157A (zh) * 2022-03-25 2023-10-03 星希尔生物科技(上海)有限公司 一种噁二唑衍生物及其制备方法和用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1549640A4 (de) * 2002-06-17 2008-08-06 Merck & Co Inc 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)azetidin-3-carboxylate und 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)pyrrolidin-3-carboxylate als edg-rezeptoragonisten
JP2006528980A (ja) * 2003-05-15 2006-12-28 メルク　エンド　カムパニー　インコーポレーテッド Ｓ１ｐ受容体作働薬としての３−（２−アミノ−１−アザシクロ）−５−アリール−１，２，４−オキサジアゾール類
AU2004277947A1 (en) * 2003-10-01 2005-04-14 Merck & Co., Inc. 3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as S1P receptor agonists
EP1893591A1 (de) * 2005-06-08 2008-03-05 Novartis AG Polycyclische oxadiazole oder isoxazole und deren verwendung als sip-rezeptorliganden

Also Published As

Publication number Publication date
US20100048639A1 (en) 2010-02-25
GB0625648D0 (en) 2007-01-31
EP2091950A1 (de) 2009-08-26
ES2352859T3 (es) 2011-02-23
EP2091950B1 (de) 2010-09-22
DE602007009420D1 (de) 2010-11-04
WO2008074820A1 (en) 2008-06-26

Similar Documents

Publication Publication Date Title
ATE482210T1 (de) Oxadiazolderivate als s1p1-rezeptor-agonisten
MY156822A (en) Indole derivatives as s1p1 receptor agonists
EA200970967A1 (ru) Оксадиазол замещенные производные индазола для применения в качестве агонистов сфингозин 1-фосфата (sip)
EA201100503A1 (ru) Глюкозидные производные и их применения
MX384206B (es) Formulaciones de inhibidores de dpp iv
EA200870475A1 (ru) Ингибиторы 11-бета-гидроксистероид-дегидрогеназы типа 1
EA200870472A1 (ru) Ингибиторы 11-бета-гидроксистероид-дегидрогеназы типа 1
EA200901133A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
MX2010005861A (es) Agonistas novedosos de los receptores de glucocorticoides.
DE602007010781D1 (de) N- (phenylmethyl) -2- (1h-pyrazol-4-yl) acetamid-derivate als p2x7-antagonisten zur behandlung von schmerzen, entzündungen und neurodegeneration
EA201070327A1 (ru) Катехоламиновые производные и их пролекарства
EA200970302A1 (ru) Тиофенпиразолопиримидиновые соединения
EA200801997A1 (ru) Новые соединения
GEP20135744B (en) Quinuclidine carbonate derivatives and medicinal compositions containing the same
TW200637874A (en) Peptides with neuropeptide-2 receptor (Y2R) agonist activity
EA200970065A1 (ru) Производные пиперазинила, предназначенные для лечения заболеваний, опосредованных рецептором gpr38
ATE542795T1 (de) Benzylpiperazinderivate als motilin- rezeptorantagonisten
TW200740814A (en) Compounds
TW200745122A (en) New compounds I
MEP1008A (xx) 3-aminociklopentankarboksamidi kao modulatori receptora hemokina
MY157425A (en) Substituted oxindole derivatives and the use thereof for the treatment of vasopressin-dependent illnesses
MX2008002805A (es) Derivados de carboxamida como antagonistas del receptor muscarinico.
DE602006018713D1 (de) Als agonisten für den nikotinischen acetylcholinrezeptor geeignete azabicycloalkanderivate
EA201100502A1 (ru) Гликозидные производные и их применения
ATE474834T1 (de) Als agonisten des gpr38-rezeptors geeignete biarylverbindungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties